Violeta Balinskaite1, Alan P Johnson2,3, Alison Holmes3, Paul Aylin1,3. 1. Dr Foster Unit, Department of Primary Care and Public Health, Imperial College London, United Kingdom. 2. National Infection Service, Public Health England, United Kingdom. 3. National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, United Kingdom.
Abstract
BACKGROUND: The Quality Premium was introduced in 2015 to financially reward local commissioners of healthcare in England for targeted reductions in antibiotic prescribing in primary care. METHODS: We used a national antibiotic prescribing dataset from April 2013 until February 2017 to examine the number of antibiotic items prescribed, the total number of antibiotic items prescribed per STAR-PU (specific therapeutic group age/sex-related prescribing units), the number of broad-spectrum antibiotic items prescribed, and broad-spectrum antibiotic items prescribed, expressed as a percentage of the total number of antibiotic items. To evaluate the impact of the Quality Premium on antibiotic prescribing, we used a segmented regression analysis of interrupted time series data. RESULTS: During the study period, over 140 million antibiotic items were prescribed in primary care. Following the introduction of the Quality Premium, antibiotic items prescribed decreased by 8.2%, representing 5933563 fewer antibiotic items prescribed during the 23 post-intervention months, as compared with the expected numbers based on the trend in the pre-intervention period. After adjusting for the age and sex distribution in the population, the segmented regression model also showed a significant relative decrease in antibiotic items prescribed per STAR-PU. A similar effect was found for broad-spectrum antibiotics (comprising 10.1% of total antibiotic prescribing), with an 18.9% reduction in prescribing. CONCLUSIONS: This study shows that the introduction of financial incentives for local commissioners of healthcare to improve the quality of prescribing was associated with a significant reduction in both total and broad-spectrum antibiotic prescribing in primary care in England.
BACKGROUND: The Quality Premium was introduced in 2015 to financially reward local commissioners of healthcare in England for targeted reductions in antibiotic prescribing in primary care. METHODS: We used a national antibiotic prescribing dataset from April 2013 until February 2017 to examine the number of antibiotic items prescribed, the total number of antibiotic items prescribed per STAR-PU (specific therapeutic group age/sex-related prescribing units), the number of broad-spectrum antibiotic items prescribed, and broad-spectrum antibiotic items prescribed, expressed as a percentage of the total number of antibiotic items. To evaluate the impact of the Quality Premium on antibiotic prescribing, we used a segmented regression analysis of interrupted time series data. RESULTS: During the study period, over 140 million antibiotic items were prescribed in primary care. Following the introduction of the Quality Premium, antibiotic items prescribed decreased by 8.2%, representing 5933563 fewer antibiotic items prescribed during the 23 post-intervention months, as compared with the expected numbers based on the trend in the pre-intervention period. After adjusting for the age and sex distribution in the population, the segmented regression model also showed a significant relative decrease in antibiotic items prescribed per STAR-PU. A similar effect was found for broad-spectrum antibiotics (comprising 10.1% of total antibiotic prescribing), with an 18.9% reduction in prescribing. CONCLUSIONS: This study shows that the introduction of financial incentives for local commissioners of healthcare to improve the quality of prescribing was associated with a significant reduction in both total and broad-spectrum antibiotic prescribing in primary care in England.
Authors: Philip Emeka Anyanwu; Koen Pouwels; Anne Walker; Michael Moore; Azeem Majeed; Benedict W J Hayhoe; Sarah Tonkin-Crine; Aleksandra Borek; Susan Hopkins; Monsey Mcleod; Céire Costelloe Journal: BJGP Open Date: 2020-08-25
Authors: Olivia Hawkins; Anna Mae Scott; Amy Montgomery; Bevan Nicholas; Judy Mullan; Antoine van Oijen; Chris Degeling Journal: PLoS One Date: 2022-01-14 Impact factor: 3.240
Authors: Martin C Gulliford; Xiaohui Sun; Judith Charlton; Joanne R Winter; Catey Bunce; Olga Boiko; Robin Fox; Paul Little; Michael Moore; Alastair D Hay; Mark Ashworth Journal: BMJ Open Date: 2020-02-28 Impact factor: 2.692